Immunis receives FDA clearance for Phase II sarcopenic obesity therapy trial

The US Food and Drug Administration (FDA) has granted clearance to Immunis to proceed with its Phase II clinical trial for IMMUNA, an investigational secretome aimed at reversing sarcopenic obesity.

The trial will assess the efficacy of IMMUNA in improving mobility and independence for individuals with this condition.